Vedolizumab: clinical trials recruiting now
14
Recruiting trials
15
Conditions studied
28
US states with sites
33
Countries
FDA drug label
- FDA-approved
- Yes. Vedolizumab appears in the FDA drug-label database. Marketed as ENTYVIO, ENTYVIO Pen, Entyvio.
- Drug class
- Integrin Receptor Antagonist (FDA established pharmacologic class)
- Mechanism of action
- Integrin Receptor Antagonists (as stated on the FDA label)
FDA-approved use
ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). moderately to severely active Crohn's disease (CD). ENTYVIO is an integrin receptor antagonist indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). ( 1 ) moderately to severely active Crohn's disease (CD). ( 1 )
Phase breakdown
Phase 1 1
Phase 2 2
Phase 3 1
Phase 4 6
Not applicable 4
Conditions being studied
Recruiting trials involving Vedolizumab
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- Autologous Stem Cell Transplant for Crohn's Disease
- Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
- Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
- Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis
- Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis
- Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
- Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
- Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis
- The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis
- The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis
- VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
Common questions
Is Vedolizumab FDA-approved?
Yes, marketed as ENTYVIO, ENTYVIO Pen, Entyvio.
How many recruiting trials involve Vedolizumab?
14 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.